Signaling beneath the Cell Surface
This article was originally published in Start Up
Designing molecules that target protein-protein interactions in transmembrane proteins, where antibodies and fragments cannot penetrate, has been difficult. Using computational methods, a group at Penn has created novel peptides that could offer a new class of reagents for studying membrane-protein folding, assembly, and signal transduction. More broadly, they could provide access to an entire new class of targets for the design of therapeutics and drug delivery systems
You may also be interested in...
PolyMedix uses a suite of proprietary, patented computational tools to create simple, easily synthesized organic small molecule compounds that mimic the activity of host defense proteins. The company's first focus is to create antibiotic candidates, and eventually, drugs for cancer and cardiovascular disease. It will seek nearer-term revenues from materials applications of its technologies.
A new publication offers up proof of concept that the genetic signatures of microorganisms found in blood and tumor tissue could improve precision medicine cancer diagnostics. The study also bolsters the notion that targeting the microbiome could lead to innovative cancer therapies.
A better understanding of heme trafficking could lead to drug targets in metabolic diseases, anemias, porphyrias, hemolytic diseases such as sickle cell disease – even parasitic infections.